Klus Pharma Inc.
Clinical trials sponsored by Klus Pharma Inc., explained in plain language.
-
New hope for tough cancers: experimental drug targets tumors resistant to standard therapy
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 1,410 participants will receive t…
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests a new drug called SKB264, given alone or with other treatments, for people with advanced or spreading non-small cell lung cancer. About 356 adults with specific genetic types of lung cancer will take part. The goal is to see if the drug shrinks tumors and is safe…
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, SKB264 and pembrolizumab, in people with advanced cancers like cervical, bladder, ovarian, prostate, and endometrial cancer. The goal is to see if the combo can shrink tumors and control the disease. About 240 adults with specific soli…
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC